Lupin announces skin ointment launch in the US
09 October 2018 | News
It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Pharma major Lupin has announced the launch of Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.’s Temovate Ointment, 0.05%. It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Clobetasol Propionate Ointment USP 0.05% had annual sales of approximately $ 93.4 million in the US.
